REGENPRP™-HA COMBINATION FOR KNEE OA
BARAC 2018The new treatment approach in knee osteoarthritis: Efficacy of cellular matrix combination of platelet rich plasma with hyaluronic acid versus two different types of hyaluronic acid (HA).
Cellular Matrix technology: a safe, fast and novel treatment approach for knee OA.
Fifty-three patients (90 knees), aged 39-80 years, suffering from knee osteoarthritis (Kellgren-Lawrence Grade I-III) were enrolled in a prospective randomised controlled clinical study comparing the clinical efficacy of RegenPRP™-HA with two different types of HA: a non-crosslinked sodium hyaluronate (AV) and a non-crosslinked sodium hyaluronate combined with mannitol (OP).
• CM group (19 patients, 30 knees): 3 injections (3 mL RegenPRP™ + 2 mL HA) every 15 days
• AV group (19 patients, 30 knees): a weekly injection of HA (2 mL) for a total of 3 weeks
• OP group (15 patients, 30 knees): a weekly injection of HA + mannitol (2 mL) for a total of 3 weeks.
RESULTS
• Pain and functional outcomes, assessed using the VAS, WOMAC, KOOS and IKDC scores, showed a statistically significant improvement at 2, 6 and 12 months after the last injection compared to baseline values.
• The improvement in the CM group was significantly better compared to the other two groups at 2 months and highly significant (p<0.01) at 6 months and 12 months.
• Statistically significant improvement of the cartilage thickness was observed at 2, 6 and 12 months after the end of RegenPRP™-HA treatment on both lateral (p<0.05), and medial (p<0.01) compartments.
The RegenPRP™-HA combination results in a longer and sustained clinical improvement than HA alone, and thus might be a useful tool for postponing arthroplasty.
REFERENCE
9. Barac, B., et al. (The new treatment approach in knee osteoarthritis: Efficacy of cellular matrix combination of platelet rich plasma with hyaluronic acid versus two different types of hyaluronic acid (HA). Int. J. Clin. Rheumatol. 2018;13(5):289-95
